This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Heidrick & Struggles Adds New Partner To Meet The Growing Convergence Of Digital And Health

CHICAGO, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Heidrick & Struggles International (Nasdaq:HSII), the premier professional services firm focused on serving the leadership needs of top organizations globally, today announced Phyllis Schneble has joined the firm as Partner within the Life Sciences and Consumer Practices. She is based in the firm's New York office.

Today, there is a dramatic movement towards total integration within the healthcare sector as consumers seek out new innovations and resources regarding personal health. Schneble will leverage her expertise with clients globally, focusing on key relationships within the pharmaceutical, consumer health and digital technology communities.

"Phyllis offers a unique intersection of knowledge and consulting skill to both our clients and our global teams," said Charlie Moore, Global Practice Managing Partner and of the firm's Healthcare and Life Sciences Practice. "It is a definitive trend that consumers are taking their health into their own hands, significantly shifting the landscape. Our clients look for and value our anticipation of future global trends, so her joining our firm makes our team even stronger."

Schneble comes to Heidrick & Struggles with more than 20 years in the healthcare sector, the majority of which was spent as a senior-level marketer for some of the top Fortune 500 pharmaceutical companies. Prior to joining, Phyllis led sales & marketing for dLife, For Your Diabetes Life – a venture capital-backed digital start up with consumer-facing properties in web, video, social media and mobile channels. She has helped to launch consumer marketing campaigns for billion-dollar drugs and more recently developed patient engagement programs delivered via health plans and systems clinically proven to increase self-care behaviors and improve outcomes.

"Over the past six decades, we've been consistently growing our depth of talent and expanding into the healthcare and consumer sector - it is a strategic priority for the firm to bridge those two worlds," said Moore.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,629.46 +188.87 1.08%
S&P 500 2,093.33 +25.69 1.24%
NASDAQ 5,091.1030 +51.3270 1.02%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs